Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W5HK
|
||||
| Former ID |
DAP000006
|
||||
| Drug Name |
Sorafenib
|
||||
| Synonyms |
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Advanced renal cell carcinoma [ICD9: 189; ICD10:C64] | Approved | [528230], [541050] | ||
| Hepatocellular carcinoma; NSCLC; Melanoma [ICD9: 155, 162, 172; ICD10:C22.0, C33, C34, C43] | Phase 3 | [537114], [541050] | |||
| Myelodysplastic syndrome; AML; Head and neck cancer; Breast cancer; Pancreatic cancer [ICD9: 140-149, 140-229, 157, 183, 205.0; ICD10:C07-C14, C25, C32, C33, C56, C92.0] | Phase 2 | [537114], [541050] | |||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bayer AG; Onyx Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H16ClF3N4O3
|
||||
| InChI |
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
|
||||
| InChIKey |
MLDQJTXFUGDVEO-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 284461-73-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
833589, 833590, 7886069, 9372814, 12015507, 14720365, 14834034, 30419984, 46505329, 46516901, 50069824, 50070560, 50071324, 50100118, 50112741, 53787819, 53799234, 56312334, 56312336, 56312338, 56312517, 56312519, 56312521, 56394953, 57399755, 68529952, 74382940, 75518900, 81092852, 85174603, 85285882, 85845166, 91148447, 92718861, 93581025, 96025209, 99443909, 103420820, 103904444, 104178872, 113461200, 117695450, 117871124, 124767621, 124893320, 124893321, 124893322, 124893323, 124893324, 125346960
|
||||
| ChEBI ID |
ChEBI:50924
|
||||
| SuperDrug ATC ID |
L01XE05
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [528230] | |
| Mast/stem cell growth factor receptor | Target Info | Modulator | [528230] | ||
| Beta platelet-derived growth factor receptor | Target Info | Modulator | [528230] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Melanogenesis | |||||
| Pathways in cancer | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancerhsa04010:MAPK signaling pathway | |||||
| Calcium signaling pathway | |||||
| Gap junction | |||||
| Regulation of actin cytoskeleton | |||||
| HTLV-I infection | |||||
| MicroRNAs in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| Choline metabolism in cancer | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkcmyb_pathway:C-MYB transcription factor network | |||||
| Signaling events mediated by Stem cell factor receptor (c-Kit)ptp1bpathway:Signaling events mediated by PTP1B | |||||
| S1P3 pathway | |||||
| Nectin adhesion pathway | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| PDGFR-beta signaling pathway | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| PDGF receptor signaling network | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| Integrin cell surface interactions | |||||
| EPHA-mediated growth cone collapse | |||||
| VEGFA-VEGFR2 Pathway | |||||
| VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling | |||||
| Regulation of KIT signaling | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| RAF/MAP kinase cascadeR-HSA-1257604:PIP3 activates AKT signaling | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Focal Adhesion | ||||
| Nifedipine Activity | |||||
| Cardiac Progenitor Differentiation | |||||
| Signaling by VEGF | |||||
| AngiogenesisWP304:Kit receptor signaling pathway | |||||
| Differentiation Pathway | |||||
| Signaling by SCF-KIT | |||||
| PIP3 activates AKT signaling | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBaseWP51:Regulation of Actin Cytoskeleton | |||||
| MAPK Signaling Pathway | |||||
| Osteoblast Signaling | |||||
| PDGF Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Signaling by PDGF | |||||
| References | |||||
| Ref 528230 | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. | ||||
| Ref 537114 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
| Ref 541050 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.